Heather Robinette
Women's Health · Moorestown, NJNPI 1508407206
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $301 and has fallen 92.1% since, to $24 in 2025.
Across 25 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$51
- Dexcom, Inc.$46
- Cequr Corporation$37
- Amneal Pharmaceuticals LLC$34
- Chiesi USA, Inc.$33
- Johnson & Johnson$24
- plus $262 from 15 others
What the payments were for
- Food & beverage$487100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 3 | $51 |
| Dexcom, Inc. | 2 | $46 |
| Cequr Corporation | 1 | $37 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Chiesi USA, Inc. | 1 | $33 |
| Johnson & Johnson | 1 | $24 |
| Bayer | 1 | $24 |
| Corcept Therapeutics | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| AbbVie | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Exeltis, USA Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Mylan Pharmaceuticals Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Theracosbio, LLC | 1 | $15 |
| Medtronic | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
How this compares
$487 in reported general payments places this provider in the 65th percentile of 182 women's health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 192 | $327,089 |
| TrulicityDulaglutide | 83 | $128,998 |
| JanuviaSitagliptin Phosphate | 67 | $81,743 |
| JardianceEmpagliflozin | 68 | $69,865 |
| MounjaroTirzepatide | 42 | $61,761 |
| TradjentaLinagliptin | 40 | $40,250 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $32,827 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 69 | $29,900 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $26,904 |
| FarxigaDapagliflozin Propanediol | 15 | $23,003 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 168 | $22,200 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $20,221 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $17,465 |
| Humalog Kwikpen U-100Insulin Lispro | 44 | $14,547 |
| Bydureon BciseExenatide Microspheres | 16 | $14,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $19 | $327,089192 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $51 | $190,759125 claims |
| AbbVieSynthroid | $20 | $2,39228 claims |
| Sanofi-aventis U.S. LLCLantus | $18 | $1,30412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $34 | $1,291133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 182 women's health providers in New Jersey.
Other women's health in Moorestown
- Kathie OlsonLawrenceville$5K
- Valerie FultonPennsauken$5K
- Patience AssobmoNewark$5K
- Lorraine HarrisPennsauken$4K
- Edita LuansingRidgewood$4K
- Seton CiagliaOradell$3K
- Kelsey DenningToms River$3K
- Alyssa DallicardilloBarnegat$3K
- Marisa Buonanno-HamrahWest Orange$2K
- Michelle GavalaSpringfield$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.